In fiscal 2025, which ended Jan 2, 2026, Exelixis, Inc. generated $884.3 million of cash from operations, up 26.3% from the year before. It spent $8.4 million on capital expenditures. That left free cash flow of $875.8 million. The company returned $947.5 million in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Oct 2, 2026
|
FY 2025
Jan 2, 2026
|
FY 2024
Jan 3, 2025
|
FY 2023
Dec 29, 2023
|
FY 2022
Dec 30, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Jan 1, 2021
|
FY 2019
Jan 3, 2020
|
FY 2018
Dec 28, 2018
|
FY 2017
Dec 29, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
28
-6.5%
|
29
+0.9%
|
29
+12.0%
|
26
+23.2%
|
21
+53.2%
|
14
+49.1%
|
9
+9.5%
|
8
+69.8%
|
5
+314.1%
|
1
+18.5%
|
1
-28.7%
|
| Stock-based compensation |
110
-7.4%
|
113
+20.4%
|
94
-11.8%
|
106
-1.1%
|
108
-10.2%
|
120
+14.0%
|
105
+85.6%
|
57
+39.3%
|
41
+69.7%
|
24
+4.5%
|
23
+4.3%
|
| Operating cash flow |
1,173
+48.3%
|
884
+26.3%
|
700
+110.0%
|
333
-8.1%
|
363
-9.5%
|
401
+91.8%
|
209
-60.3%
|
527
+26.8%
|
416
+151.0%
|
166
-19.7%
|
206
+245.7%
|
| Investing | |||||||||||
| Capital expenditures |
12
+6.4%
|
8
-70.4%
|
28
-29.7%
|
40
+46.1%
|
28
-48.9%
|
54
+78.7%
|
30
+136.4%
|
13
-61.5%
|
33
+57.5%
|
21
+1141.5%
|
2
+281.0%
|
| Investing cash flow |
61
-73.5%
|
350
+400.1%
|
-117
-333.3%
|
-27
+94.9%
|
-524
-1122.9%
|
-43
+67.3%
|
-131
+77.7%
|
-587
-97.2%
|
-298
-909.5%
|
37
+117.0%
|
-216
-531.4%
|
| Financing | |||||||||||
| Debt repaid |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
0
-100.0%
|
186
|
—
|
| Stock buybacks |
1,261
+43.2%
|
948
+45.3%
|
652
+18.5%
|
550
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
-1,305
-44.6%
|
-970
-54.2%
|
-629
-15.2%
|
-546
-93282.9%
|
1
+104.0%
|
-15
+41.1%
|
-25
-300.2%
|
13
+29.5%
|
10
+105.7%
|
-170
-958.0%
|
20
-87.0%
|
| Change in cash | |||||||||||
| Net change in cash |
-72
-160.6%
|
265
+681.1%
|
-46
+81.0%
|
-240
-48.7%
|
-161
-147.0%
|
343
+551.9%
|
53
+210.3%
|
-48
-137.4%
|
128
|
—
|
—
|
| Free cash flow |
1,161
+48.9%
|
876
+30.4%
|
672
+129.3%
|
293
-12.6%
|
335
-3.4%
|
347
+94.0%
|
179
-65.3%
|
514
+34.4%
|
382
+164.7%
|
144
-29.4%
|
205
+244.0%
|
| Per share | |||||||||||
| Free cash flow per share |
4.38
+61.0%
|
3.11
+37.0%
|
2.27
+148.9%
|
0.91
-11.7%
|
1.03
-4.0%
|
1.08
+91.4%
|
0.56
-65.6%
|
1.63
+33.5%
|
1.22
+164.0%
|
0.46
|
—
|
| Shareholder returns | |||||||||||
| Returned to shareholders |
1,261
|
948
|
652
|
550
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Share of free cash flow |
108.60%
|
108.18%
|
97.10%
|
187.94%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | |||||||||||
| Free cash flow margin |
46.50%
|
37.75%
|
30.96%
|
16.00%
|
20.79%
|
24.15%
|
18.09%
|
53.12%
|
44.79%
|
31.93%
|
106.86%
|
| Capital expenditures to revenue |
0.48%
|
0.36%
|
1.31%
|
2.21%
|
1.72%
|
3.78%
|
3.07%
|
1.33%
|
3.90%
|
4.67%
|
0.89%
|
| Stock-based compensation to revenue |
4.42%
|
4.87%
|
4.33%
|
5.81%
|
6.68%
|
8.35%
|
10.64%
|
5.85%
|
4.76%
|
5.29%
|
11.97%
|
| Cash conversion |
1.33x
|
1.13x
|
1.34x
|
1.60x
|
1.99x
|
1.73x
|
1.87x
|
1.64x
|
0.60x
|
1.07x
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.